Monocyte-derived circulating microparticles (CD14⁺, CD14⁺/CD11b⁺ and CD14⁺/CD142⁺) are related to long-term prognosis for cardiovascular mortality in STEMI patients

详细信息    查看全文

• 作者：Gemma Chiva-Blanch^a ; ^b ; ^c ; ¹ ; ^{GChiva@santpau.cat} ; Vibeke Bratseth^a ; Vibeke Ritschel^a ; ^b ; Geir Ø ; . Andersen^d ; Sigrun Halvorsen^b ; ^d ; Jan Eritsland^d ; Harald Arnesen^a ; ^b ; Lina Badimon^c ; Ingebjø ; rg Seljeflot^a ; ^b ; ^d
• 关键词：AMI ; acute myocardial infarction ; AV ; Annexin V ; CVD ; cardiovascular disease ; cMPs ; circulating microparticles ; CAD ; coronary artery disease ; CV ; cardiovascular ; CD ; cluster of differentiation ; CVE ; cardiovascular event ; HF ; heart failure ; MACE ; major adverse cardiovascular event ; PCI ; percutaneous coronary intervention ; PS ; phosphatidylserine ; SMC ; smooth muscle cells ; STEMI ; ST-elevation myocardial infarction ; TF ; CD142 ; tissue factor
• 刊名：International Journal of Cardiology
• 出版年：2017
• 出版时间：15 January 2017
• 年：2017
• 卷：227
• 期：Complete
• 页码：876-881
• 全文大小：551 K
• 卷排序：227

文摘

Circulating microparticles (cMPs) are emerging as biomarkers of cardiovascular disease (CVD). We analyzed cMPs in 200 STEMI patients in a median of 28 h after the onset of symptoms. Monocyte-derived cMPs in the acute phase of STEMI are related to the long-term prognosis for CV death. These findings may be a useful tool to improve prognosis at the long-term in STEMI patients.